Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 08:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Reports Third Quarter 2025 Financial and Operating Results

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery...
November 10, 2025 08:01 ET | Source: Voyager Therapeutics, Inc.

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging...
August 26, 2025 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today...
August 06, 2025 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Reports Second Quarter 2025 Financial and Operating Results

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - ...
July 16, 2025 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s...
June 10, 2025 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today...
May 15, 2025 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced...
May 06, 2025 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Reports First Quarter 2025 Financial and Operating Results

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – ...
April 28, 2025 16:30 ET | Source: Voyager Therapeutics, Inc.

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data...
March 31, 2025 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical...